Treatment guidelines in adult women

Acne Vulgaris

Volumn , Issue , 2011, Pages 198-207

  Villasenor, Jennifer ^a   Berson, Diane S ^b   Kroshinsky, Daniela ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890927073     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (55)

1. Thiboutot DM, Knaggs H, Gilliland K, et al. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136(2):166-171.
2. Klaus W, Richard Allen J, eds. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. 6th ed. New York: The McGraw-Hill Companies, 2009.
3. Pochi PE, Strauss JS. Sebaceous gland response in man to the administration of testosterone, delta-4-androstenedione, and dehydroisoandrosterone. J Invest Dermatol 1969; 52(1):32-36.
4. Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol 1974; 62(3):191-201.
5. Strauss JS, Kligman AM, Pochi PE. The effect of androgens and estrogens on human sebaceous glands. J Invest Dermatol 1962; 39:139-155.
6. Thody AJ, Shuster S. Control and function of sebaceous glands. Physiol Rev 1989; 69(2):383-416.
7. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996; 106(1):176-182.
8. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169(3):1535-1541.
9. Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone. Arch Dermatol 1994; 130(3):308-314.
10. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37(5 pt 1):746-754.
11. Cibula D, Hill M, Vohradnikova O, et al. The role of androgens in determining acne severity in adult women. Br J Dermatol 2000; 143(2):399-404.
12. Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999; 135(9):1041-1045.
13. Beylot C, Doutre MS, Beylot-Barry M. Oral contraceptives and cyproterone acetate in female acne treatment. Dermatology 1998; 196(1):148-152.
14. Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age. Arch Dermatol 1991; 127(2):210-216.
15. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49(1 suppl):S1-S37.
16. Olutunmbi Y, Paley K, English JC III. Adolescent female acne: etiology and management. J Pediatr Adolesc Gynecol 2008; 21(4):171-176.
17. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and therapies. Semin Cutan Med Surg 2001; 20(3):144-153.
18. Thiboutot DM. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol 2001; 15(suppl 3):57-61.
19. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995; 98(1A):89S-94S.
20. Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin Dermatol 2004; 22(5):412-418.
21. Faure M, Drapier-Faure E. [Hormonal treatments of acne]. Ann Dermatol Venereol 2003; 130(1 pt 2):142-147.
22. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56(4):651-663.
23. van Wayjen RG, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes 1995; 103(4):241-251.
24. Sawaya ME, Hordinsky MK. The antiandrogens. When and how they should be used. Dermatol Clin 1993; 11(1):65-72.
25. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984; 111(2):209-214.
26. Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5 alpha-dihydrotestosterone in vitro. J Invest Dermatol 1993; 100(5):660-662.
27. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne:an update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol 2009; 60(5 suppl 1):S1-S50.
28. Krunic A, Ciurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone. J Am Acad Dermatol 2008; 58(1):60-62.
29. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther 2006; 19(4):210-223.
30. Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 1994; 61(2):281-287.
31. Wysowski DK, Freiman JP, Tourtelot JB, et al. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118(11):860-864.
32. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? Facts and controversies. Clin Dermatol 2010; 28(1):17-23.
33. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med 2002; 47(11 suppl):975-980.
34. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997; 89(4):615-622.
35. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a lowdose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril 2001; 76(3):461-468.
36. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/ 20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77(4):249-256.
37. Arowojolu AO, Gallo MF, Grimes DA, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004; (3):CD004425.
38. James WD. Acne. N Engl J Med 2005; 352(14):1463-1472.
39. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis 2004; 74(2):123-130.
40. World Health Organization. Improving Access to Quality Care in Family Planning:Medical Eligibilty Criteria for Contraceptive Use. 2nd ed. Geneva, Switzerland:World Health Organization, 2003.
41. World Health Organization. Improving Access to Quality Care in Family Planning:Medical Eligibility Criteria for Contraceptive Use. 2nd ed. Geneva, Switzerland:World Health Organization, 2003.
42. Frangos JE, Alavian CN, Kimball AB. Acne and oral contraceptives: update on women's health screening guidelines. J Am Acad Dermatol 2008; 58(5):781-786.
43. Harper JC. Antiandrogen therapy for skin and hair disease. Dermatol Clin 2006; 24(2):137-143, v.
44. Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335(2):126-136.
45. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46(6):917-923.
46. Helms SE, Bredle DL, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997; 36(5 pt 1):705-710.
47. London BM, Lookingbill DP. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Arch Dermatol 1994; 130(3):392-393.
48. Degitz K, Placzek M, Arnold B, et al. Congenital adrenal hyperplasia and acne in male patients. Br J Dermatol 2003; 148(6):1263-1266.
49. Faloia E, Filipponi S, Mancini V, et al. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. J Endocrinol Invest 1993; 16(9):675-677.
50. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004; 22(5):419-428.
51. Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther 2008; 21(2):86-95.
52. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 2002; 119(5):992-1007.
53. Thiboutot D, Jabara S, McAllister JM, et al. Human skin is a steroidogenic tissue:steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 2003; 120(6):905-914.
54. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206(1):37-53.
55. Orfanos CE, Adler YD, Zouboulis CC. The SAHA syndrome. Horm Res 2000; 54(5-6):251-258.